Journal Scans
Radiotherapy Plus Cetuximab for Locoregionally Advanced Head and Neck Cancer
RT Plus Cetuximab for Advanced Head and Neck Cancer
JA Bonner, PM Harari, J Giralt, RB Cohen, CU Jones, RK Sur, D Raben, J Baselga, SA Spencer, J Zhu, H Youssoufian, EK Rowinsky, KK Ang
20100001
2010 Jan 1
Lancet Oncol
Radiotherapy Plus Cetuximab for Locoregionally Advanced Head and Neck Cancer
Lancet Oncol. 2010 Jan 1;11(1):21-28, JA Bonner, PM Harari, J Giralt, RB Cohen, CU Jones, RK Sur, D Raben, J Baselga, SA Spencer, J Zhu, H Youssoufian, EK Rowinsky, KK Ang
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Previous results from our phase 3 randomised trial showed that adding cetuximab to primary radiotherapy increased overall survival in patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN) at 3 years. Here we report the 5-year survival data, and investigate the relation between cetuximab-induced rash and survival. Methods: Patients with LASCCHN of the oropharynx, hypopharynx, or larynx with measurable disease were randomly allocated in a 1:1 ratio...
